Oppenheimer & Co. Inc. Raises Holdings in AstraZeneca PLC (NASDAQ:AZN)

Oppenheimer & Co. Inc. boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZNGet Rating) by 1.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,602 shares of the company’s stock after acquiring an additional 203 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in AstraZeneca were worth $836,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. US Bancorp DE boosted its holdings in AstraZeneca by 15.7% during the 1st quarter. US Bancorp DE now owns 116,733 shares of the company’s stock valued at $7,745,000 after acquiring an additional 15,870 shares during the period. Intersect Capital LLC raised its position in AstraZeneca by 35.6% during the 1st quarter. Intersect Capital LLC now owns 4,656 shares of the company’s stock valued at $309,000 after purchasing an additional 1,223 shares during the last quarter. Moneta Group Investment Advisors LLC bought a new position in AstraZeneca during the 1st quarter valued at approximately $218,000. Bank of New York Mellon Corp raised its position in AstraZeneca by 61.0% during the 1st quarter. Bank of New York Mellon Corp now owns 849,299 shares of the company’s stock valued at $56,341,000 after purchasing an additional 321,867 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC raised its position in AstraZeneca by 12.5% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 15,490 shares of the company’s stock valued at $1,028,000 after purchasing an additional 1,720 shares during the last quarter. 21.55% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Stock Down 1.8 %

AZN stock opened at $60.69 on Friday. AstraZeneca PLC has a twelve month low of $53.63 and a twelve month high of $71.70. The company has a quick ratio of 0.67, a current ratio of 0.96 and a debt-to-equity ratio of 0.74. The firm has a market cap of $188.07 billion, a PE ratio of -148.02, a price-to-earnings-growth ratio of 1.27 and a beta of 0.42. The business has a 50 day moving average of $66.06 and a 200 day moving average of $65.42.

AstraZeneca Cuts Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Monday, September 12th. Investors of record on Friday, August 12th will be given a dividend of $0.465 per share. This represents a yield of 2.2%. The ex-dividend date of this dividend is Thursday, August 11th. AstraZeneca’s dividend payout ratio (DPR) is presently -221.95%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on AZN shares. TheStreet lowered AstraZeneca from a “b-” rating to a “c” rating in a research report on Tuesday. Citigroup upped their price target on AstraZeneca from £105 ($126.87) to £130 ($157.08) in a research report on Tuesday, July 12th. Argus raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Monday, August 29th. StockNews.com raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Monday, July 11th. Finally, AlphaValue raised AstraZeneca to a “reduce” rating in a research report on Monday, August 22nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and an average price target of $8,840.50.

About AstraZeneca

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

See Also

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.